KIT and gastrointestinal stromal tumor: Ripretinib, a TKI that was primarily designed to inhibit c‐kit and PDGFRα but also inhibits Tie2 and VEGFR2 (Smith et al,2019), has been approved for use as a salvage therapy for mutant c‐kit expressing gastrointestinal stromal tumors (Dhillon, 2020).